Phase I trial of @entity19981 with whole body @entity221 in XXXX .

@entity1 @entity320 @entity706 @entity5 @entity2 @entity149 @entity344 @entity420 @entity19981 @entity925 @entity221 @entity71140
@entity19981 is a dechlorinated derivative of @entity71140 which preclinically synergizes with @entity221 . Clinically, this nonmyelosuppressive drug (given p.o. daily) is active as a single agent in a variety of @entity5 . On this basis, a Phase I study which incorporates a drug escalation schema as well as an escalation in temperature, i.e., 41.0 degrees C for 85 min to 41.8 degrees C for 75 min, was executed. Induction therapy included seven whole-body @entity221 treatments. Whole-body @entity221 was delivered using a radiant heat system. Twenty-four @entity1 were entered on study. Of these, 20 were evaluable for response. Group A (60 mg/m2) had three @entity1 with three no responses. Group B (180 mg/m2) consisted of three @entity1 : one @entity706 , partial response; two @entity344 , one partial response and one improvement, i.e., less than a partial response. Group C (360 mg/m2) had 17 @entity1 : two @entity2 , one complete response and one improvement; one @entity320 , improvement; one ovarian, disease stabilization (greater than 100 days); two @entity420 of the gastrointestinal tract, two disease stabilizations; 11 @entity1 , no responses; one @entity1 entered at this level was ineligible for study and did not receive @entity19981 . Therapy was well tolerated. Of 16 @entity1 reporting @entity925 , two required a @entity19981 dose reduction; one @entity1 required dose reduction for @entity149 . Results obtained encourage Phase II clinical trials.
